Bone Biologics Co. (NASDAQ:BBLG) Sees Significant Growth in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 28,700 shares, an increase of 129.6% from the August 31st total of 12,500 shares. Approximately 5.5% of the company’s shares are short sold. Based on an average daily trading volume, of 4,820,000 shares, the short-interest ratio is currently 0.0 days.

Bone Biologics Stock Performance

Bone Biologics stock opened at $2.35 on Friday. Bone Biologics has a 1 year low of $0.80 and a 1 year high of $10.56. The firm has a 50 day moving average price of $1.66 and a 200 day moving average price of $1.67.

Bone Biologics (NASDAQ:BBLG) last issued its earnings results on Friday, August 9th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($1.39) by $0.72. Equities research analysts expect that Bone Biologics will post -3.17 earnings per share for the current fiscal year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.